Aura Biosciences (NASDAQ:AURA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $19.00 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 15.15% from the stock’s previous close.
According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. “
Shares of Aura Biosciences stock traded down $0.27 during trading on Wednesday, hitting $16.50. 48,070 shares of the stock traded hands, compared to its average volume of 36,003. The firm’s fifty day moving average is $18.70 and its 200-day moving average is $18.40. Aura Biosciences has a 52 week low of $13.50 and a 52 week high of $26.16.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Citigroup Inc. bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $31,000. New York State Common Retirement Fund bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $45,000. California State Teachers Retirement System bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $51,000. Wells Fargo & Company MN bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $55,000. Finally, Deutsche Bank AG bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 51.69% of the company’s stock.
About Aura Biosciences (Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Indie Semiconductor Stock is Putting in a Bottom
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.